Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children

被引:6
作者
Stolbova, Sarka [1 ,2 ]
Bezdicka, Martin [1 ,2 ]
Prohaszka, Zoltan [3 ,4 ]
Csuka, Dorottya [3 ,4 ]
Hrachovinova, Ingrid [5 ]
Burkert, Jan [2 ,6 ]
Simankova, Nadezda [1 ,2 ]
Pruhova, SStepanka [1 ,2 ]
Zieg, Jakub [1 ,2 ]
机构
[1] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic
[2] Motol Univ Hosp, Prague, Czech Republic
[3] Hungarian Acad Sci, Dept Med 3, Budapest, Hungary
[4] Hungarian Acad Sci, MTA SE Res Grp Immunol & Haematol, Budapest, Hungary
[5] Inst Hematol & Blood Transfus, Prague, Czech Republic
[6] Charles Univ Prague, Fac Med 2, Dept Cardiovasc Surg, Prague, Czech Republic
关键词
Alternative complement pathway; Anti-complement factor H antibodies; Atypical haemolytic uraemic syndrome; Children; DGKE; Next-generation sequencing; FACTOR-H-AUTOANTIBODIES; COMPLEMENT MUTATIONS; ECULIZUMAB; IMPACT; GENE; CFHR1;
D O I
10.1007/s00431-020-03666-9
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Atypical haemolytic uraemic syndrome is an ultra-rare, life-threatening disease. Causative variants in genes that encode complement factors can be identified in 40-70% of cases. We performed genetic analysis of 21 Czech children with atypical haemolytic uraemic syndrome. Genetic or acquired predisposition to the disease was identified in the majority of our patients: CFHR1 and CFHR3 deletions in 14/21 (67%; 13 of them were positive for anti-complement factor H antibodies), variants in complement genes or DGKE in 13/21 (62%). Multiple genetic findings were identified in eight patients (38%). The incidence of atypical haemolytic uraemic syndrome in the Czech paediatric population was estimated to be 0.092 (CI 0.053-0.131) cases per million inhabitants and 0.92 (CI 0.53-1.32) cases per 100,000 births for the entire reporting period. Ten patients were initially treated with plasma exchange and eight with eculizumab or with a combination of eculizumab and plasma exchange. At the last follow-up, 20 patients were alive and one patient had end-stage renal disease. Conclusion: The incidence of atypical haemolytic uraemic syndrome in the Czech paediatric population corresponds to the reported incidence in Europe. We detected the unusually high rate of CFHR1/CFHR3 deletions associated with anti-complement factor H antibodies in Czech paediatric patients. Treatment by eculizumab led to superior outcomes and prevention of the disease relapses compared with plasma exchange therapy. Our results may help to understand the polygenic nature of atypical haemolytic uraemic syndrome as a disease that results from a combination of various risk factors.What is Known: center dot Atypical haemolytic uraemic syndrome (aHUS) is considered a polygenic and multifactorial disease. Genetic predisposition to aHUS is identified in 40-70% of children. center dot Anti-complement factor H antibodies are usually found in 6-25% of affected children.What is New: center dot Potentially causative genetic or acquired factors were confirmed in the majority of patients. The prevailing finding was the unusually high rate of CFHR1/CFHR3 deletions associated with anti-complement factor H antibodies (62% of patients). center dot The incidence of aHUS in Czech children is 0.092 (CI 0.053-0.131) cases per million inhabitants and 0.92 (CI 0.53-1.32) cases per 100,000 births for the entire reporting period.
引用
收藏
页码:1739 / 1750
页数:12
相关论文
共 50 条
  • [1] Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children
    Šárka Štolbová
    Martin Bezdíčka
    Tomas Seeman
    Zoltán Prohászka
    Dorottya Csuka
    Ingrid Hrachovinová
    Jan Burkert
    Naděžda Šimánková
    Štěpánka Průhová
    Jakub Zieg
    European Journal of Pediatrics, 2020, 179 : 1739 - 1750
  • [2] Eculizumab in secondary atypical haemolytic uraemic syndrome
    Cavero, Teresa
    Rabasco, Cristina
    Lopez, Antia
    Roman, Elena
    Avila, Ana
    Sevillano, Angel
    Huerta, Ana
    Rojas-Rivera, Jorge
    Fuentes, Carolina
    Blasco, Miquel
    Jarque, Ana
    Garcia, Alba
    Mendizabal, Santiago
    Gavela, Eva
    Macia, Manuel
    Quintana, Luis F.
    Maria Romera, Ana
    Borrego, Josefa
    Arjona, Emi
    Espinosa, Mario
    Portoles, Jose
    Gracia-Iguacel, Carolina
    Gonzalez-Parra, Emilio
    Aljama, Pedro
    Morales, Enrique
    Cao, Mercedes
    Rodriguez de Cordoba, Santiago
    Praga, Manuel
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (03) : 466 - 474
  • [3] Molecular basis of complement factor I deficiency in Tunisian atypical haemolytic and uraemic syndrome patients
    Jlajla, Hend
    Dehman, Fatma
    Jallouli, Manel
    Khedher, Rania
    Ayadi, Imen
    Zerzeri, Yosr
    Laadhar, Lilia
    Sfar, Imen
    Mahfoudh, Abdelmajid
    Gorgi, Yosr
    Cheour, Elhem
    Zouaghi, Karim
    Gargah, Tahar
    Sellami, Maryam Kallel
    NEPHROLOGY, 2019, 24 (03) : 357 - 364
  • [4] A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome
    Westra, D.
    Wetzels, J. F. M.
    Volokhina, E. B.
    van den Heuvel, L. P.
    van de Kar, N. C. A. J.
    NETHERLANDS JOURNAL OF MEDICINE, 2012, 70 (03) : 121 - 129
  • [5] The long-term outcomes of atypical haemolytic uraemic syndrome: a national surveillance study
    Durkan, Anne M.
    Kim, Siah
    Craig, Jonathan
    Elliott, Elizabeth
    ARCHIVES OF DISEASE IN CHILDHOOD, 2016, 101 (04) : 387 - 391
  • [6] Cardiovascular complications in atypical haemolytic uraemic syndrome
    Noris, Marina
    Remuzzi, Giuseppe
    NATURE REVIEWS NEPHROLOGY, 2014, 10 (03) : 174 - 180
  • [7] Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab
    Verhave, Jacobien C.
    Wetzels, Jack F. M.
    van de Kar, Nicole C. A. J.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 131 - 141
  • [8] Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
    Macia, Manuel
    de Alvaro Moreno, Fernando
    Dutt, Tina
    Fehrman, Ingela
    Hadaya, Karine
    Gasteyger, Christoph
    Heyne, Nils
    CLINICAL KIDNEY JOURNAL, 2017, 10 (03): : 310 - 319
  • [9] Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
    Wong, Edwin K. S.
    Goodship, Tim H. J.
    Kavanagh, David
    MOLECULAR IMMUNOLOGY, 2013, 56 (03) : 199 - 212
  • [10] Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome
    Verhave, J. C.
    Westra, D.
    van Hamersvelt, H. W.
    van Helden, M.
    van de Kar, N. C. A. J.
    Wetzels, J. F. M.
    NETHERLANDS JOURNAL OF MEDICINE, 2013, 71 (07) : 342 - 347